We expect Novo to gain $75 billion of a more than $200 billion global GLP-1 market in diabetes and obesity by 2031, ahead of semaglutide's 2032 patent expiration, with Lilly standing as the firm's key ...

Novo Nordisk today announced 2024 earnings, reporting a 26% increase in annual sales to ~$40.56bn. Read why I upgrade NVO ...

Taking a compounded GLP-1 medication isn’t the same thing as your pharmacy filling a cheaper, generic version of the drug ...

Rybelsus (semaglutide) is a brand-name prescription medication that ... Factors such as whether a drug is a brand name or generic contribute to the tier. A drug’s tier determines a person’s copayment ...

Hims & Hers may leverage FDA compounding exemptions to further extend its compounded GLP-1 offerings. Learn why HIMS stock is ...

Ozempic, the drug that was originally approved to treat type 2 diabetes, has now also been approved by the FDA to reduce ...

In recent years, the pharmaceutical industry has undergone significant changes in the focus of its innovation, research and ...

Dr Reddy's shares tumbled up to 6% in early trade and at 9:46 am, they were trading 4.35% lower at Rs 1,233.25 on the Bombay ...

THESE MEDICATIONS ARE MOSTLY KNOWN FOR TREATING DIABETES AND OBESITY.. BUT THE F-D-A HAS APPROVED THEM FOR PREVENTING HEART ...

“So, I am pre-diabetic. And I am on semaglutide.” Semaglutide is the generic form of the drug Ozempic, according to the University of California Davis. It was approved in 2017 by the U.S. Food ...

Lots of people are on cheaper compounded weight-loss drugs that mimic brands like Ozempic, Wegovy, and Zepbound. They're about to lose access.

Only 34 of 79 websites stated that compounded drugs were not FDA approved; 39 websites did not report adverse effects, warnings.